Aurobindo Pharma Ltd has lined up around 30-40 products for launch in the US market in the present financial year and the next.

Out of this pipeline, at least 10 products have already been approved, according to PV Ramprasad Reddy, Executive Chairman, Aurobindo Pharma USA.

The US has been a major market for the Hyderabad-based company. Of a total revenue of ₹13,533 crore from formulations, US market revenue stood at ₹7,442 crore in the year ended March 31, 2018, an increase of 9 per cent over previous year. The growth was primarily driven by the new product launches and improved volumes of existing products.

Formulations business contributed 82 per cent of total revenue during 2017-18.

Some products are on the verge of receiving approvals. In injectables segment, Aurobindo is likely to get approval for Ertapenem soon as per the information provided by the firm in the recent analyst call.

“We have heard that our Drug Master File (DMF) got cleared...If there are no further queries, which hopefully should not be there, we should get approval in the next few days to few weeks,’’ N Govindarajan, Managing Director, said.

The company will launch the product in a couple of weeks after the approval. However, as the product is a sensitive product and it has to be in cold storage in terms of API level, it is “cautious.’’

European market

For European markets, Aurobindo has about 200 products under development. During FY18, it had two major launches and says similar launches ``will continue.’’

As a business strategy, the drug-maker has been diversifying its markets. “Our objective is to grow across and we would also like to ensure that we are spread well geogrpahically,’’ Govindarajan said.

Today, US and Europe together brings 67 per cent of revenue. With growth being registered registered in Europe, it can even be better foing forward.

Related Topics
comment COMMENT NOW